Synstar PLC
23 June 2004
23 June 2004
Synstar signs full Managed IT Services contract with Avecia
Synstar plc ('Synstar' or 'the Group') is pleased to announce that it has signed
a full Managed IT Services contract with Avecia, a leading global fine and
specialty chemicals company. This will increase the value of Synstar's
relationship with Avecia to circa £19 million in the next 3 years.
Synstar is already a trusted supplier to Avecia and has, for a number of years,
provided IT maintenance and helpdesk support services. Under the terms of this
additional contract, which begins on 1 July 2004, Synstar will be providing IT
infrastructure and applications support to Avecia's key locations. As part of
the agreement, 54 Avecia staff and some full-time contractors will transfer to
Synstar.
The agreement provides for a possible extension of a further three years after
the initial three-year contract period.
Steve Vaughan, Chief Executive of Synstar commented today:
'This contract demonstrates that we are continuing to fulfil the strategy
outlined 6 months ago which sees Synstar pursuing larger, more complex Managed
Services contracts. Our agreement with Avecia delivers a broad range of IT
managed services to a company that is itself focused on delivering innovative
technology and service excellence to customers. The contract will help us
deliver on our plans for profit improvement driven by revenue growth.'
Derrick Nicholson, CFO of Avecia added:
'In outsourcing the majority of our IT requirements to Synstar, we are building
on an established relationship with a company we see as a trusted supplier in
the field of IT management. The deal also provides continuity for Avecia with
the transfer of staff and full time contractors skilled in a broad range of IT
services.'
Steve Vaughan / Stephen Gleadle
Synstar Plc Tel: 01344 662700
Edward Bridges / James Melville-Ross
Financial Dynamics Tel: 020 7831 3113
Avecia - A World Leader in Fine and Specialty Chemicals
Avecia is a leading global fine and specialty chemicals company focused on
delivering innovative technology and service excellence to customers across a
range of high technology industries.
With unique capabilities in organic chemistry, biological & polymer sciences and
process technology, each of our business sectors offers bespoke products and
services to our global customers, supported by highly focused technical
expertise.
Avecia is divided into three divisions - Biotechnology, Chemicals, NeoResins -
with a rich history and long track record of innovation and service excellence.
Avecia operates at the leading edge of technology investing ca 10% of annual
turnover in research, development and process technology.
The knowledge and skills of our international workforce of 2500+ employees have
pioneered many important products which are in everyday use.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.